Metabolic · Placeholder catalog data
GLP-3 (R)
Also known as LY3437943
A next-generation synthetic peptide engineered as a unimolecular triple agonist at the GIP, GLP-1, and glucagon receptors. Actively studied in Phase 2/3 trials and a major object of incretin literature.
130 credits
Paid from your credit pool at checkout. Bulk quantities discount automatically.
Available variants
Pricing and fulfillment information is placeholder data.
| Amount | SKU | Credits | MSRP | Availability | Margin estimate |
|---|---|---|---|---|---|
| 5 mg | PTS-RET-5 | 26 credits | $99 | Ready | 74% estimate |
| 10 mg | PTS-RET-10 | 32 credits | $149 | Ready | 79% estimate |
| 20 mg | PTS-RET-20 | 51 credits | $199 | Ready | 74% estimate |
| 30 mg | PTS-RET-30 | 58 credits | $229 | Ready | 75% estimate |
| 60 mg | PTS-RET-60 | 115 credits | $349 | 10 business days | 67% estimate |
Margin estimate treats 1 credit as $1 and compares estimated wholesale credit cost with placeholder MSRP. It excludes shipping, taxes, and other costs.
Buy more, save more
Quantity breaks apply per line item and are deducted automatically at checkout.
| Quantity per line | Discount | Example (5 mg unit) |
|---|---|---|
| 10+ units | 5% off | 10 × 26 credits → 247 credits |
| 25+ units | 10% off | 25 × 26 credits → 585 credits |
| 50+ units | 15% off | 50 × 26 credits → 1,105 credits |
| 100+ units | 20% off | 100 × 26 credits → 2,080 credits |
Specifications
- CAS
- 2381089-83-2
- Formula
- C221H343N51O64
- Molecular weight
- 4731.37 g/mol
- Sequence
- YXQGTFTSDYSIYLDKKAQXAFIEYLLEGGPSSGAPPPS (Aib substitutions; C20 diacid)
- Purity
- ≥99%
- Appearance
- White lyophilized powder
- Storage
- Store lyophilized at 2–8 °C, protected from light and moisture
Quality record
COA status
COA listedLot PTS-RET-2607
Placeholder reference. Verify the active lot before ordering.
Research background
Retatrutide is a synthetic peptide engineered as a balanced agonist at three metabolic receptors simultaneously: GIP, GLP-1, and glucagon. The molecule represents a significant step in the evolution of incretin-pathway tools, extending the dual-agonist concept of Tirzepatide with an added glucagon component intended to engage hepatic and thermogenic pathways.
Published Phase 2 literature has reported substantial effects on body weight, hepatic fat, and glycemic endpoints in study populations with obesity and type 2 diabetes. Phase 3 programs are ongoing as of the most recent publications.
Supplied as a research-grade reference peptide for investigation of triple-agonist incretin pharmacology. Not supplied for therapeutic use.
Mechanism: Literature describes Retatrutide as a balanced triple agonist at GIPR, GLP-1R, and GCGR, engaging incretin pathways alongside hepatic glucagon signaling.
Research use only
For research use only. Not for human or veterinary use.